



## **Aptinyx to Present at Ladenburg Thalmann and Cantor Fitzgerald Healthcare Conferences**

September 21, 2017

**Evanston, Ill., September 21, 2017** – Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced that Norbert G. Riedel, Ph.D., President and CEO, will present an overview of the company and its research and development at two healthcare investor conferences in New York City on Tuesday, September 26th, 2017. At 9:30 a.m. Eastern Time, he will present at the Ladenburg Thalmann 2017 Healthcare Conference. Later that day, at 4:35 p.m. Eastern Time, Dr. Riedel will present at the Cantor Fitzgerald Global Healthcare Conference.

### **About Aptinyx**

Aptinyx Inc. is a clinical-stage biopharmaceutical company discovering and developing transformative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovery of novel compounds that work through a unique mechanism to modulate – rather than block or over-activate – NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. Drugs that modulate NMDA receptors in this distinct way have both robust efficacy and exceptionally favorable safety. The company's lead drug candidate, NYX-2925, is in Phase 2 clinical development as a therapy for neuropathic pain, an area of significant unmet need. Aptinyx is also advancing additional compounds from its proprietary chemistry platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit [www.aptinyx.com](http://www.aptinyx.com).